Director Mark Stolper to leave board at 2025 annual meeting; board rebalanced

Coherus Oncology, Inc.

Mark D. Stolper notified Board he will not stand for re-election at 2025 annual meeting; departure not due to any disagreement.
Stolper will serve until election of directors at 2025 Annual Meeting, then expected to consult through Dec 31, 2026.
Board decreased authorized directors from 10 to 9, effective upon Stolper's departure.
Rita A. Karachun reclassified from Class II to Class I; Michael Ryan from Class III to Class II to balance board classes.
Board now has three Class I, four Class II, and three Class III directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Mark D. Stolper

Director

CHRS · Coherus Oncology, Inc.

Filed: April 25, 2025, 7:59 PM ET

On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark D. Stolper departed as Director at Coherus Oncology, Inc..

Action: not stand for re-election
Role: Director

Exact text from the filing

On April 22, 2025, Mark D. Stolper, a member of the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”), notified the Board of his intention not to stand for re-election to the Board for an additional three-year term at the Company's 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”).

View on SEC.gov

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-25-005554

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.